BioNTech (BNTX) Stock Forecast, Price & News

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares.
View BNTX analyst ratings or view top-rated stocks.

13 Wall Street research analysts have issued 12 month price objectives for BioNTech's shares. Their BNTX share price forecasts range from $120.00 to $260.00. On average, they anticipate the company's share price to reach $171.07 in the next year. This suggests a possible upside of 56.2% from the stock's current price.
View analysts price targets for BNTX or view top-rated stocks among Wall Street analysts.

BioNTech's stock was trading at $150.22 at the beginning of the year. Since then, BNTX shares have decreased by 27.1% and is now trading at $109.50.
View the best growth stocks for 2023 here.

BioNTech saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 2,020,000 shares, an increase of 5.2% from the April 30th total of 1,920,000 shares. Based on an average daily volume of 699,600 shares, the short-interest ratio is currently 2.9 days.
View BioNTech's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our BNTX earnings forecast.

BioNTech SE (NASDAQ:BNTX) issued its quarterly earnings data on Monday, May, 8th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $0.18 by $1.87. The company earned $1.28 billion during the quarter, compared to the consensus estimate of $1.09 billion. BioNTech had a trailing twelve-month return on equity of 32.52% and a net margin of 51.03%. BioNTech's quarterly revenue was down 80.0% on a year-over-year basis. During the same quarter last year, the company earned $15.98 EPS.

ETFs with the largest weight of BioNTech (NASDAQ:BNTX) stock in their portfolio include Direxion mRNA ETF (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX) and Loncar Cancer Immunotherapy ETF (CNCR).

33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

(BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

BioNTech trades on the NASDAQ under the ticker symbol "BNTX."

BioNTech's stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.10%), Flossbach Von Storch AG (1.41%), Artisan Partners Limited Partnership (1.07%), BlackRock Inc. (0.79%), Envestnet Asset Management Inc. (0.40%) and Twin Tree Management LP (0.00%).

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BNTX stock can currently be purchased for approximately $109.50.

BioNTech (NASDAQ:BNTX) has a market capitalization of $26.63 billion and generates $18.24 billion in revenue each year. The company earns $9.94 billion in net income (profit) each year or $26.01 on an earnings per share basis.

The company employs 4,530 workers across the globe.

BioNTech's mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The official website for the company is www.biontech.de. The company can be reached via phone at 49-61-31908-40, via email at investors@biontech.de, or via fax at 49-6131-908-4390.